Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA.
J Gastrointest Surg. 2011 Jan;15(1):165-74. doi: 10.1007/s11605-010-1378-5. Epub 2010 Nov 17.
Pancreatic adenosquamous carcinoma has historically been characterized as having a more aggressive clinical course than ductal adenocarcinoma. The natural history of this disease, however, is essentially unknown.
We evaluated the clinical characteristics of all patients with pancreatic adenosquamous carcinoma recorded in the California Cancer Registry 2000-2007 and compared them to those of patients with ductal adenocarcinoma.
Ninety-five patients with pancreatic adenosquamous carcinoma and 14,746 patients with ductal adenocarcinoma were identified. Demographics were similar between subtypes (p > 0.05). Disease stage at presentation was also similar; over 50% of each diagnostic group presented with metastatic disease (p = 0.62). Surgical resection was more common among patients with locoregional adenosquamous carcinoma than adenocarcinoma (p = 0.0004), but rates of adjuvant therapy administration were similar (p > 0.05). The cohorts' median overall survival durations were similar in a Cox proportional hazards model (p = 0.45); overall survival was also similar when only patients with resected disease were considered (p = 0.65). Early stage, resection and receipt of radiation or chemotherapy were favorable independent prognostic factors among patients with adenosquamous carcinoma. The median overall survival duration of patients with resected adenosquamous carcinoma was 12 months (95% CI, 8-52).
Adenosquamous carcinoma has a natural history similar to that of ductal adenocarcinoma when treated with prevalent clinical patterns of care.
胰腺腺鳞癌的临床病程比导管腺癌更具侵袭性，这在历史上已有定论。然而，这种疾病的自然病程基本上是未知的。
我们评估了 2000-2007 年加利福尼亚癌症登记处记录的所有胰腺腺鳞癌患者的临床特征，并将其与导管腺癌患者进行了比较。
共确定了 95 例胰腺腺鳞癌患者和 14746 例导管腺癌患者。两组患者的人口统计学特征相似（p>0.05）。疾病分期在两组中也相似；超过 50%的每个诊断组患者均为转移性疾病（p=0.62）。局部区域性腺鳞癌患者的手术切除率高于腺癌（p=0.0004），但辅助治疗的应用率相似（p>0.05）。在 Cox 比例风险模型中，两组的中位总生存时间相似（p=0.45）；仅考虑接受手术治疗的患者时，总生存时间也相似（p=0.65）。早期、切除、接受放疗或化疗是腺鳞癌患者的独立预后良好因素。接受手术治疗的腺鳞癌患者的中位总生存时间为 12 个月（95%CI，8-52）。
当采用目前常见的治疗模式时，腺鳞癌的自然病程与导管腺癌相似。
